Gilead Sciences, Inc. vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.21. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals.
| GILD | QCLN | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $68.47 |
52-Week Low | $110.56 | $36.11 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
QCLN trades at $53.09, up 2.0% with a bullish technical signal from moving averages. The ETF benefits from clean energy sector momentum driven by data center power demand and global energy security concerns. Recent news highlights clean energy ETF gains amid volatile oil markets, though regulatory challenges and supply chain pressures present headwinds. Key support sits at $51-52 with resistance at $53-55.
The outlook remains positive given structural energy transition trends, but investors face regulatory uncertainty from U.S. permit delays and China trade tensions. Wall Street sentiment leans bullish on clean energy themes, though valuation metrics are unavailable for this ETF. Risks include geopolitical supply chain disruptions and policy shifts affecting renewable project economics.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →